Disclosure Statement
NLH
Financial disclosures: E.M. has received research support, consultant income, or own stocks of the following companies: Apple, Huami, Jazz Pharmaceutical, Suven, Harmony Biosciences, Avidel, Eisai, Centessa Pharmaceutical, Idorsia, Takeda, and Vanda. R.K.B. is a shareholder of WaterMark Medical and Healthy Humming, LLC; is on the board of directors of WaterMark Medical; serves as a consultant to Jazz Pharmaceuticals, Harmony Biosciences, Avadel Pharmaceuticals, Takeda, and Oventus; conducts industry-funded research for Avadel Pharmaceuticals, Axsome Therapeutics, Bresotec Medical, Bayer, Idorsia, Suven Life Sciences, Jazz Pharmaceuticals, Balance Pharma Inc., NLS Pharmaceutics, Vanda Pharmaceuticals Inc., Merck, Eisai Co. Ltd, Philips, Fresca Medical, Takeda, LivaNova, Roche, Sanof, Sommetrics, and Noctrix Health; and has served on the speakers’ bureau for Jazz Pharmaceuticals, Eisai Co. Ltd., and Harmony Biosciences. H.E. has received research support from the following companies: Jazz Pharmaceuticals, Suven Life Sciences, Harmony Biosciences, NLH Pharmaceuticals, Avadel, ApniMed, Takeda Pharmaceutical, Axsome Therapeutics, Inc., Expansion Therapeutics, Idorsia Pharmaceuticals, and Vanda Pharmaceuticals, and discloses advisory board participation for ApniMed, Inc, Harmony Biosciences, Avadel and Takeda Pharmaceutical. N.F.-S. has served on advisory board and publication committees for Jazz Pharmaceuticals, and has received research support from Jazz, Suven and Takeda. M.N., R.N., H.F., T.S., and T.O. are employees of and stockholders in Takeda Pharmaceuticals Company Limited. Non-financial disclosures: None.